Participants are randomly assigned to receive either the active drug or the placebo, and neither the participants nor the study staff know which is given (double‑blind). The treatment is administered periodically over a period of about two years, with regular visits to assess thinking abilities using tools such as the MoCA test, and to monitor overall disease symptoms with scales like the MDS‑UPDRS. Safety is checked through routine lab tests, blood pressure measurements, and ECG recordings to watch for any side effects.

After a qualifying attack, participants are randomly assigned to receive either the experimental infusion or the placebo, both given through a vein. They continue the usual steroid treatment and are followed for about three months, with visits to check vision, strength, walking speed, hand dexterity, and overall disability using simple tests and questionnaires. The study records whether additional rescue treatments are needed, how quickly symptoms improve, and any side effects, allowing researchers to see if the added drug provides a meaningful benefit.

Participants in the study will take lasmiditan as needed for their migraine attacks over a 12-month period. The study will monitor how well the medication is tolerated by the participants and will track any side effects that may occur. The study will also look at how many participants stop using the medication due to any adverse effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how lasmiditan works in treating migraines in children. This research aims to provide valuable insights into the long-term use of lasmiditan for managing migraines in pediatric patients.

The purpose of the study is to assess the effectiveness of a predefined OCS tapering schedule in adult participants with Generalized Myasthenia Gravis treated with ravulizumab and oral steroids. Participants start with a regular dose of the oral steroid and then follow a step‑by‑step plan to gradually lower (taper) the dose over several weeks, while receiving regular check‑ups to monitor muscle strength and overall health. The study follows participants for a few months, including visits at the beginning, after the tapering period is finished, and during a follow‑up phase to see if the steroid dose can be reduced or stopped without worsening the disease or causing problems such as adrenal insufficiency, a condition where the body’s stress‑hormone production is low.

The purpose of the study is to evaluate the safety and effectiveness of Cinryze in managing the acute phase of subarachnoid hemorrhage. Participants in the study will receive either Cinryze or a placebo through an IV infusion, which means the treatment is given directly into a vein. The study will monitor participants for any complications during their hospital stay and assess their neurological condition over a period of 14 days. Researchers will also look at the activity of the complement system in the blood and spinal fluid, as well as other factors like the length of stay in the intensive care unit and the number of days on a ventilator.

By temporarily blocking the complement system, the study aims to limit the risk of delayed cerebral ischemia, a condition where the brain does not get enough blood flow, which can occur after a subarachnoid hemorrhage. The hope is that this approach will lead to better recovery and outcomes for patients by reducing the body’s inflammatory response. The trial is expected to start recruiting participants in November 2024 and aims to complete by August 2025.

The main goal of the trial is to assess the safety and tolerability of the drug. Participants will take the study tablet for about three months and will have regular visits where blood samples are taken and brain imaging is performed to look at signs of inflammation in the brain, known as neuroinflammation. Simple explanations of technical terms are provided: pharmacokinetics refers to how the body absorbs, distributes, and removes the drug, while pharmacodynamics describes how the drug affects the body’s cells and systems.

Throughout the study, researchers will watch for any side effects, record any health problems that arise, and compare laboratory and imaging results from the start of the trial to the end of the treatment period to understand how the drug influences disease activity.

The purpose of the study is to see whether the active drug can lower the risk of brain ischemia and related clot‑related problems after the bleed. Over a period of 14 days, participants are monitored for signs of blood clots that could block vessels (thromboembolic events) and for any neurological worsening. Doctors use a brain scan called MRI and a scoring system known as NIHSS to check for new areas of damage, and they also watch for a condition called delayed cerebral ischemia, which is a later reduction in blood flow that can happen after the initial bleed. After the treatment period, follow‑up visits and scans are done to assess recovery.

Participants will take the study tablets once daily for about 12 weeks and will attend regular clinic visits where they will complete questionnaires and undergo simple tests. One questionnaire, the Epworth Sleepiness Scale, asks about the likelihood of falling asleep in everyday situations to measure daytime sleepiness. Another test, the Maintenance of Wakefulness Test, measures how long a person can stay awake while trying to stay alert. Throughout the study, researchers will monitor how the medication affects sleepiness and overall well‑being, while also checking for any side effects.

The purpose is to find out whether AST-004 can protect the brain and be safe for patients with this type of injury. Participants will receive a single infusion of either the study drug or the placebo shortly after their injury, remain in the hospital for a brief observation period, and then attend a few follow‑up visits over roughly one month.

During the follow‑up, blood samples will be taken to measure a protein called GFAP that indicates brain cell damage, and a special brain scan using MR spectroscopy will be performed to examine brain chemistry. Researchers will monitor for any side effects and record changes in how patients feel and function.